Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma
Luiza Martins Nascentes Melo(German Cancer Research Center), Iris Helfrich(German Cancer Research Center), Dayana Herrera-Rios(West Cancer Center), Nicole Glodde(University of Bonn), Jean‐Christophe Marine(VIB-KU Leuven Center for Cancer Biology), Michael Hölzel(University of Bonn), Stefanie Löffek(German Cancer Research Center), Niklas Uhlenbrock(TU Dortmund University), Helmut Hanenberg(Indiana University – Purdue University Indianapolis), Juliane Klein(Deutschen Konsortium für Translationale Krebsforschung), Isa-Vanessa Westedt(German Cancer Research Center), Dirk Schadendorf(National Center for Tumor Diseases), Florian Rambow(Essen University Hospital), Alexandra Brenzel(Essen University Hospital), Maike Effern(University of Bonn), Antje Sucker(German Cancer Research Center), Jadwiga Jabłońska(German Cancer Research Center), Sara Egea‐Rodriguez(West German Heart and Vascular Center Essen), Joanna Poźniak(VIB-KU Leuven Center for Cancer Biology), Yahya Al-Matary(German Cancer Research Center), Sonia Leonardelli(University of Bonn), Maja Bau(German Cancer Research Center), Daniel Rauh(TU Dortmund University), Roberta Turiello(University Hospital Bonn), Florian Wirsdörfer, Daniel Hinze(University of Bonn), Irem Oezel(University of Duisburg-Essen), Eva Hadaschik(West German Heart and Vascular Center Essen)
Cited by 31
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
|Journal of Clinical Oncology|2015|2.1k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k